ERYTECH Pharma's Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency.

The article informs that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has adopted a positive opinion to grant orphan drug designation to the company ERYTECH Pharma's investigational product ENHOXY for sickle cell disease. ENHOXY enhances the oxygenation properties of red blood cells by reducing their oxygen-hemoglobin affinity and allowing them to release more oxygen.